Get the Industry Trends Report
Back to blog December 19, 2017 No Comments Author: Andy Jones

Private Equity Investments in Public Healthcare Companies

Private equity firms currently hold 221 positions in publicly-traded healthcare companies. The majority of these are pharmaceutical companies, followed by biotechnology companies.

PE investments in Public Healthcare Companies

Pharma

Top private equity firms investing in public Pharmaceutical companies

  1. Foresite Capital – 34 positions
  2. OrbiMed Advisors – 19 positions
  3. Aisling Capital – 14 positions
  4. TPG – 5 positions
  5. Essex Woodlands – 5 positions

Examples: Private Equity Investments in public Pharmaceutical companies

  • Foresite Capital invested in SAGE Therapeutics (SAGE). Market Cap = $6.8 billion
  • OrbiMed Advisors invested in CTI BioPharma (CTIC). Market Cap = $113 million
  • Aisling Capital invested in GTX (GTXI). Market Cap = $276 million
  • TPG invested in Collegium Pharmaceutical (COLL). Market Cap = $579 million
  • Essex Woodlands invested in Revance Therapeutics (RVNC). Market Cap = $1.1 billion

BioTech

Top private equity firms investing in public Biotechnology companies

  1. Foresite Capital – 17 positions
  2. OrbiMed Advisors – 6 positions
  3. Polaris Partners – 5 positions
  4. Aisling Capital – 4 positions
  5. HBM Healthcare Investments – 2 positions

Examples: Private Equity Investments in public Biotechnology companies

  • Foresite Capital invested in Jounce Therapeutics (JNCE). Market Cap = $471 million
  • OrbiMed Advisors invested in Xtant Medical (XTNT). Market Cap = $10.7 million
  • Polaris Partners invested in Editas Medicine (EDIT). Market Cap = $994 million
  • Aisling Capital invested in Audentes Therapeutics (BOLD). Market Cap = $852 million
  • HBM Healthcare Investments invested in Neurocrine Biosciences (NBIX). Market Cap = $6.2 billion

Related: Read our broader study of Private Equity Investments in Public Companies.